Navigation Links
Prix Galien USA Announces 2009 Final Candidates
Date:8/7/2009

ce for the amount of research and level of skill that was invested in the development of these products that improve lives," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal.

Prix Galien USA honorees are judged on the basis of the innovative nature of the development, application or clinical utility of the drug or technology and whether its discovery can be applied to future biomedical science.

In 2008, the Prix Galien USA committee recognized Selzentry(TM)( )(Pfizer Inc.), Isentress(R) (Merck & Co., Inc.), Soliris(R) (Alexion Pharmaceuticals, Inc.), INFUSE(R) (Wyeth) and Revlimid(R)( )(The Celgene Corporation).

The Prix Galien USA award is considered the industry's highest accolade for pharmaceutical research and development -- equivalent to the Nobel Prize. The award committee comprises 11 individuals including seven Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals. For details about the Prix Galien USA award and committee visit www.prix-galien-usa.com.


'/>"/>
SOURCE Prix Galien USA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Prix Galien USA Announces 2008 Final Candidates
2. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
3. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
4. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial ... The net income for the first quarter ended March ... of $14.1 million during the same period in 2010. Net ... related primarily to the $34.2 million in collaboration revenue recognized ...
... 2011 Silence Therapeutics plc (AIM: ... of patent 4,705,370, titled "Further Novel Forms of ...  The issued patent covers aspects of Silence,s platform ... 2,-O-Methyl structures known as AtuRNAi.  Silence,s AtuRNAi molecules ...
... May 2, 2011 Dendreon Corporation (Nasdaq: DNDN ) ... Revenue for the quarter ended March 31, 2011 was $28.1 million ... The GAAP net loss for the quarter ended March ... $125.7 million, or $0.96 per share for the quarter ended March ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 2Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 3Dendreon Reports First Quarter 2011 Financial Results 2Dendreon Reports First Quarter 2011 Financial Results 3Dendreon Reports First Quarter 2011 Financial Results 4Dendreon Reports First Quarter 2011 Financial Results 5
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... 25, 2012  ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... its BluScience ( www.bluscience.com ) line ... McKesson to approximately 4,000 independent drugstores and pharmacies. ...
... five leading causes of death. And yet, despite ... treatment for most cancers. In addition, disappointing results ... the need for alternative methods. Mathematical ... of tumors in terms of differential equations and ...
... Research!America,s Board chair, former Congressman John Edward Porter (R-IL), ... in basic research. , "America,s leadership is at ... in discovery and development," said Porter. "We could ... Europe integrate science and technology into economic growth while ...
Cached Biology News:ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 2ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 3ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 4Aiding cancer therapy by mathematically modeling tumor-immune interactions 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 3State of the Union speech: Promising outlook for research and innovation 2
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: